Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Mol Neurobiol ; 53(5): 3416-3427, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26081151

RESUMO

MicroRNAs (miRNAs) remain stable in circulation and have been identified as potential biomarkers for a variety of conditions. We report miRNA changes in blood from multiple rodent models of pain, including spinal nerve ligation and spared nerve injury models of neuropathic pain; a complete Freund's adjuvant (CFA) model of inflammatory pain; and a chemotherapy-induced model of pain using the histone deacetylase inhibitor JNJ-26481585. The effect of celecoxib, a cyclooxygenase-2-selective nonsteroidal anti-inflammatory drug, was investigated in the CFA model as proof of principle for assessing the utility of circulating miRNAs as biomarkers in determining treatment response. Each study resulted in a unique miRNA expression profile. Despite differences in miRNAs identified from various models, computational target prediction and functional enrichment have identified biological pathways common among different models. The Wnt signaling pathway was affected in all models, suggesting a crucial role for this pathway in the pathogenesis of pain. Our studies demonstrate the utility of circulating miRNAs as pain biomarkers and suggest the potential for rigorous forward and reverse translational approaches. Evaluating alterations in miRNA fingerprints under different pain conditions and after administering therapeutic agents may be beneficial in evaluating clinical trial outcomes, predicting treatment response, and developing correlational outcomes between preclinical and human studies.


Assuntos
MicroRNA Circulante/genética , Perfilação da Expressão Gênica , Neuralgia/sangue , Neuralgia/genética , Animais , Celecoxib/farmacologia , MicroRNA Circulante/metabolismo , Modelos Animais de Doenças , Adjuvante de Freund , Regulação da Expressão Gênica/efeitos dos fármacos , Inibidores de Histona Desacetilases/farmacologia , Ácidos Hidroxâmicos/farmacologia , Hiperalgesia/sangue , Hiperalgesia/complicações , Hiperalgesia/genética , Inflamação/patologia , Ligadura , Masculino , Camundongos Endogâmicos C57BL , Neuralgia/complicações , Neuralgia/cirurgia , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Nervos Espinhais/efeitos dos fármacos , Nervos Espinhais/cirurgia , Via de Sinalização Wnt/efeitos dos fármacos
2.
J Mol Neurosci ; 55(3): 570-8, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25085711

RESUMO

Recent studies have shown that histone deacetylase (HDAC) inhibitors can alleviate inflammatory and neuropathic pain. We investigated the effects of JNJ-26481585, a pan-HDAC inhibitor on basal mechanical sensitivity. Unlike previous reports for HDAC inhibitors, JNJ-26481585 induced mechanical hypersensitivity in mice. This effect was reversible with gabapentin. Voltage-dependent calcium channel subunit alpha-2/delta-1, one of the putative targets for gabapentin, was upregulated in the spinal cord from JNJ-26481585-treated mice. Transcriptional profiling of spinal cord from JNJ-26481585-treated mice showed significant alterations in pathways involved in axon guidance, suggesting overlap in mechanisms underlying neurotoxicity caused by other known chemotherapeutic agents. To investigate the mechanisms underlying the development of pain, RAW 264.7 mouse macrophage cells were treated with JNJ-26481585. There was a dose- and time-dependent activation of nuclear factor-kappaB and interleukin-1ß increase. Thus, alterations in the axon guidance pathway, increase in voltage-dependent calcium channel alpha(2)delta-1 subunit, and the induction of proinflammatory mediators by JNJ-26481585 could all contribute to increased mechanical sensitivity. Our data indicate that the effect of HDAC inhibitors may be unique to the compound studied and highlights the potential to develop chemotherapy-induced peripheral neuropathy with the use of a pan-HDAC inhibitor for cancer treatment, and this pain may be alleviated by gabapentin.


Assuntos
Antineoplásicos/efeitos adversos , Inibidores de Histona Desacetilases/efeitos adversos , Ácidos Hidroxâmicos/efeitos adversos , Hiperalgesia/etiologia , Neuralgia/etiologia , Aminas/farmacologia , Animais , Canais de Cálcio/genética , Canais de Cálcio/metabolismo , Ácidos Cicloexanocarboxílicos/farmacologia , Gabapentina , Hiperalgesia/metabolismo , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , NF-kappa B/metabolismo , Neuralgia/metabolismo , Medula Espinal/efeitos dos fármacos , Medula Espinal/metabolismo , Ácido gama-Aminobutírico/farmacologia
3.
J Vis Exp ; (76): e50294, 2013 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-23792786

RESUMO

Stable miRNAs are present in all body fluids and some circulating miRNAs are protected from degradation by sequestration in small vesicles called exosomes. Exosomes can fuse with the plasma membrane resulting in the transfer of RNA and proteins to the target cell. Their biological functions include immune response, antigen presentation, and intracellular communication. Delivery of miRNAs that can regulate gene expression in the recipient cells via blood has opened novel avenues for target intervention. In addition to offering a strategy for delivery of drugs or RNA therapeutic agents, exosomal contents can serve as biomarkers that can aid in diagnosis, determining treatment options and prognosis. Here we will describe the procedure for quantitatively analyzing miRNAs and messenger RNAs (mRNA) from exosomes secreted in blood and cell culture media. Purified exosomes will be characterized using western blot analysis for exosomal markers and PCR for mRNAs of interest. Transmission electron microscopy (TEM) and immunogold labeling will be used to validate exosomal morphology and integrity. Total RNA will be purified from these exosomes to ensure that we can study both mRNA and miRNA from the same sample. After validating RNA integrity by Bioanalyzer, we will perform a medium throughput quantitative real time PCR (qPCR) to identify the exosomal miRNA using Taqman Low Density Array (TLDA) cards and gene expression studies for transcripts of interest. These protocols can be used to quantify changes in exosomal miRNAs in patients, rodent models and cell culture media before and after pharmacological intervention. Exosomal contents vary due to the source of origin and the physiological conditions of cells that secrete exosomes. These variations can provide insight on how cells and systems cope with stress or physiological perturbations. Our representative data show variations in miRNAs present in exosomes purified from mouse blood, human blood and human cell culture media. Here we will describe the procedure for quantitatively analyzing miRNAs and messenger RNAs (mRNA) from exosomes secreted in blood and cell culture media. Purified exosomes will be characterized using western blot analysis for exosomal markers and PCR for mRNAs of interest. Transmission electron microscopy (TEM) and immunogold labeling will be used to validate exosomal morphology and integrity. Total RNA will be purified from these exosomes to ensure that we can study both mRNA and miRNA from the same sample. After validating RNA integrity by Bioanalyzer, we will perform a medium throughput quantitative real time PCR (qPCR) to identify the exosomal miRNA using Taqman Low Density Array (TLDA) cards and gene expression studies for transcripts of interest. These protocols can be used to quantify changes in exosomal miRNAs in patients, rodent models and cell culture media before and after pharmacological intervention. Exosomal contents vary due to the source of origin and the physiological conditions of cells that secrete exosomes. These variations can provide insight on how cells and systems cope with stress or physiological perturbations. Our representative data show variations in miRNAs present in exosomes purified from mouse blood, human blood and human cell culture media.


Assuntos
Exossomos/química , Exossomos/genética , MicroRNAs/genética , MicroRNAs/isolamento & purificação , Animais , Western Blotting , Meios de Cultura , Humanos , Camundongos , MicroRNAs/sangue , MicroRNAs/química , Reação em Cadeia da Polimerase/métodos , RNA Mensageiro/sangue , RNA Mensageiro/química , RNA Mensageiro/genética , RNA Mensageiro/isolamento & purificação
4.
Mol Biochem Parasitol ; 179(2): 100-6, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21767577

RESUMO

A putative ß-hydroxybutyrate dehydrogenase (ßHBDH) ortholog was identified in Trypanosoma brucei, the unicellular eukaryotic parasite responsible for causing African Sleeping Sickness. The trypanosome enzyme has greater sequence similarity to bacterial sources of soluble ßHBDH than to membrane-bound Type I ßHBDH found in higher eukaryotes. The ßHBDH gene was cloned from T. brucei genomic DNA and active, recombinant His-tagged enzyme (His(10)-TbßHBDH) was purified to approximate homogeneity from E. coli. ßHBDH catalyzes the reversible NADH-dependent conversion of acetoacetate to D-3-hydroxybutyrate. In the direction of D-3-hydroxybutyrate formation, His(10)-TbßHBDH has a k(cat) value of 0.19 s(-1) and a K(M) value of 0.69 mM for acetoacetate. In the direction of acetoacetate formation, His(10)-TbßHBDH has a k(cat) value of 11.2 s(-1) and a K(M) value of 0.65 mM for D-3-hydroxybutyrate. Cofactor preference was examined and His(10)-TbßHBDH utilizes both NAD(H) and NADP(H) almost equivalently, distinguishing the parasite enzyme from other characterized ßHBDHs. Furthermore, His(10)-TbßHBDH binds NAD(P)(+) in a cooperative fashion, another unique characteristic of trypanosome ßHBDH. The apparent native molecular weight of recombinant His(10)-TbßHBDH is 112 kDa, corresponding to tetramer, as determined through size exclusion chromatography. RNA interference studies in procyclic trypanosomes were carried out to evaluate the importance of TbßHBDH in vivo. Upon knockdown of TbßHBDH, a small reduction in parasite growth was observed suggesting ßHBDH has an important physiological role in T. brucei.


Assuntos
Hidroxibutirato Desidrogenase/metabolismo , Proteínas de Protozoários/metabolismo , Trypanosoma brucei brucei/enzimologia , Ácido 3-Hidroxibutírico/metabolismo , Acetoacetatos/metabolismo , Sequência de Aminoácidos , Clonagem Molecular , Ativação Enzimática , Inibidores Enzimáticos/metabolismo , Escherichia coli/genética , Escherichia coli/metabolismo , Técnicas de Silenciamento de Genes , Hidroxibutirato Desidrogenase/genética , Hidroxibutirato Desidrogenase/isolamento & purificação , Dados de Sequência Molecular , NAD/metabolismo , NADP/metabolismo , Proteínas de Protozoários/genética , Proteínas de Protozoários/isolamento & purificação , Interferência de RNA , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Alinhamento de Sequência , Especificidade por Substrato , Trypanosoma brucei brucei/genética , Trypanosoma brucei brucei/crescimento & desenvolvimento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA